Preparation and evaluation of the effect of Fe3 O4 @piroctone olamine magnetic nanoparticles on matrix metalloproteinase-2: a preliminary in vitro study.
In the present study, Fe3 O4 magnetic nanoparticles were synthesized by the coprecipitation of Fe(2+) and Fe(3+) ions and used as a nanocarrier for the production of piroctone-olamine-loaded Fe3 O4 nanoparticles (Fe3 O4 @PO NPs). The nanocrystalline structure of the prepared iron oxide species was confirmed by the X-ray diffraction spectroscopy method. Particle size distribution analysis showed that the size of Fe3 O4 @PO NPs was in the range of 5-55 nm. The magnetization curve of Fe3 O4 @PO NPs (with saturation magnetization of 28.2 emu/g) confirmed its ferromagnetic property. Loading of PO on the surface of Fe3 O4 NPs qualitatively verified by Fourier transform infrared spectrum obtained from Fe3 O4 @PO NPs. Cytotoxicity studies on the human fibrosarcoma cell line (HT-1080) revealed higher inhibitory effect of Fe3 O4 @PO NPs (50% cell death [IC50 ] of 8.1 µg/mL) as compared with Fe3 O4 NPs (IC50 of 117.1 µg/mL) and PO (IC50 of 71.2 µg/mL) alone. In the case of human normal fibroblast (Hs68), the viability percentage was found to be 75% in the presence of Fe3 O4 @PO NPs (120 µg/mL). Gelatin zymography showed 17.2% and 34.6% inhibition of matrix metalloproteinase-2 (MMP-2) in the presence of Fe3 O4 @PO and PO, respectively, at the same concentration of 40 µg/mL, whereas Fe3 O4 NPs did not inhibit MMP-2 at any concentration.
Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Mojtaba
M
Shakibaie
Mahboobe
M
Haghiri
Mandana
M
Jafari
Sahar
S
Amirpour-Rostami
Alieh
A
Ameri
Hamid
H
Forootanfar
Mitra
M
Mehrabani
D045744:Cell Line, Tumor; D004338:Drug Combinations; D004983:Ethanolamines / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D005290:Ferric Compounds / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D005347:Fibroblasts / Q000187:drug effects; D005354:Fibrosarcoma / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D058185:Magnetite Nanoparticles / Q000737:chemistry*; D020778:Matrix Metalloproteinase 2 / Q000737:chemistry*; D011728:Pyridones / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D014961:X-Ray Diffraction
D004338:Drug Combinations; D004983:Ethanolamines; D005290:Ferric Compounds; D058185:Magnetite Nanoparticles; D011728:Pyridones; C000499:ferric oxide; C052599:piroctone olamine; D020778:Matrix Metalloproteinase 2
Fe3O4; HT-1080; magnetic nanoparticles; matrix metalloproteinase-2; piroctone olamine